The Cancer Letter

Inside information on cancer research and drug development

In Brief

ACS CAN urges House leadership to refrain from tying debt limit proposal to problematic public health provisions

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

American Cancer Society Cancer Action Network sent a letter to Speaker Kevin McCarthy and House Democratic Leader Hakeem Jeffries detailing concerns on provisions in the Limit, Save and Grow Act that would restrict access to affordable health care and risk progress in cancer research.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

ACS report: Cancer mortality continues to drop despite rising incidence in women

Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% higher in 2002. In 2021, for the first time, lung cancer incidence was higher in women under 65 than in men. 
By Yiqing Wang
In the Archives

53 Nobel Prizes and counting: ACS celebrates a legacy of funding research

In a new article on the Cancer History Project, the American Cancer Society profiles three ACS-funded Nobel laureates:  David Baker, PhD2024 Nobel PrizeChemistry Victor Ambrose, PhD 2024 Nobel Prize Physiology or Medicine Gary Ruvkun, PhD2024 Nobel Prize Physiology or Medicine They join a cohort of 50 other ACS-funded Nobel laureates.  “The American Cancer Society’s legacy, with 53 Nobel...

Clinical Roundup

Medicaid expansion may improve cancer care and survival for people with HR-negative, HER2-positive breast cancer

New research published in the Journal of the National Comprehensive Cancer Network found that people with newly-diagnosed hormone receptor-negative, human epidermal growth factor receptor 2-positive breast cancer were more likely to receive timely, guideline-concordant treatment, and have longer survival in states that participate in Medicaid expansion under the Affordable Care Act.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account